We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape
Read MoreHide Full Article
Key Takeaways
TEM and GeneCentric developed PurIST to classify PDAC tumors into classical or basal subtypes.
The TEM-led study shows PurIST can guide first-line therapy choices in advanced pancreatic cancer.
Findings establish TEM's PurIST as a prognostic and predictive biomarker for improving patient survival.
Per a report by the Kenner Family Research Fund, pancreatic cancer remains one of the most lethal malignancies, with limited therapeutic options and a five-year survival rate of just 12%. For patients with advanced, unresectable pancreatic ductal adenocarcinoma (PDAC), the two most common first-line chemotherapy regimens, FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP), have shown variable efficacy.
However, the clinicians lacked robust biomarkers to guide optimal therapy selection. To address this challenge, Tempus AIInc. (TEM - Free Report) collaborated with GeneCentric to develop and deploy PurIST, a clinically validated, RNA-based algorithm test that classifies PDAC tumors as either “classical” or “basal” subtypes.
Per the Grand View Research report, the global pancreatic cancer treatment market size is projected to reach $5.84 billion by 2030, at a CAGR of 12.3% from 2025 to 2030. Factors such as unhealthy lifestyles, alcohol consumption, and obesity have been the primary causes of pancreatic cancer in patients. Based on the market prospects, Tempus’ PurIST is well-positioned to strengthen its position and contribute to its top-line growth.
Recently, the company unveiled the largest real-world evidence supporting the integration of PurIST into routine clinical care for patients with advanced PDAC. Patients were treated with either first-line FFX or GnP, and clinical outcomes were assessed according to PurIST classification.
The study’s findings establish PurIST as both a prognostic and predictive biomarker, enabling clinicians to personalize first-line therapy for patients with advanced PDAC and maximize the likelihood of improved survival. The study was published in the JCO Precision Oncology.
Recent Development by TEM Peers in the Oncology Space
Caris Life Sciences (CAI - Free Report) recently announced the publication of a study validating the analytical and clinical performance of its FDA-approved assay, MI Cancer Seek. It is used as a companion diagnostic (CDx) to identify cancer patients who may benefit from targeted therapies.
The study states that MI Cancer Seek works reliably for detecting multiple variant types of high clinical significance, and that its approved medical uses follow strict laboratory standards. It also offers the added benefit of simultaneous RNA and DNA extraction from minimal tissue input compared to other tissue-based assays that may require individual testing processes in increased tissue requirements and potential delays.
Personalis, Inc. (PSNL - Free Report) announced new favorable data for its NeXT Personal from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings demonstrate that the company’s highly sensitive molecular residual disease (MRD) test, NeXT Personal, is a strong predictor of outcomes in patients with stage II-IIIb, EGFR-mutated non-small cell lung cancer (NSCLC) receiving neoadjuvant therapy.
TEM Stock Outperforms Industry & Benchmark
In the past year, Tempus AI shares have rallied 67.4%, outperforming the industry’s 21.4% growth and the S&P 500 composite’s 19.4% improvement.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 9.56X compared with the industry average of 5.88X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's loss per share estimate for 2025 has moved south 8 cents.
Image: Bigstock
TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape
Key Takeaways
Per a report by the Kenner Family Research Fund, pancreatic cancer remains one of the most lethal malignancies, with limited therapeutic options and a five-year survival rate of just 12%. For patients with advanced, unresectable pancreatic ductal adenocarcinoma (PDAC), the two most common first-line chemotherapy regimens, FOLFIRINOX (FFX) and gemcitabine plus nab-paclitaxel (GnP), have shown variable efficacy.
However, the clinicians lacked robust biomarkers to guide optimal therapy selection. To address this challenge, Tempus AI Inc. (TEM - Free Report) collaborated with GeneCentric to develop and deploy PurIST, a clinically validated, RNA-based algorithm test that classifies PDAC tumors as either “classical” or “basal” subtypes.
Per the Grand View Research report, the global pancreatic cancer treatment market size is projected to reach $5.84 billion by 2030, at a CAGR of 12.3% from 2025 to 2030. Factors such as unhealthy lifestyles, alcohol consumption, and obesity have been the primary causes of pancreatic cancer in patients. Based on the market prospects, Tempus’ PurIST is well-positioned to strengthen its position and contribute to its top-line growth.
Recently, the company unveiled the largest real-world evidence supporting the integration of PurIST into routine clinical care for patients with advanced PDAC. Patients were treated with either first-line FFX or GnP, and clinical outcomes were assessed according to PurIST classification.
The study’s findings establish PurIST as both a prognostic and predictive biomarker, enabling clinicians to personalize first-line therapy for patients with advanced PDAC and maximize the likelihood of improved survival. The study was published in the JCO Precision Oncology.
Recent Development by TEM Peers in the Oncology Space
Caris Life Sciences (CAI - Free Report) recently announced the publication of a study validating the analytical and clinical performance of its FDA-approved assay, MI Cancer Seek. It is used as a companion diagnostic (CDx) to identify cancer patients who may benefit from targeted therapies.
The study states that MI Cancer Seek works reliably for detecting multiple variant types of high clinical significance, and that its approved medical uses follow strict laboratory standards. It also offers the added benefit of simultaneous RNA and DNA extraction from minimal tissue input compared to other tissue-based assays that may require individual testing processes in increased tissue requirements and potential delays.
Personalis, Inc. (PSNL - Free Report) announced new favorable data for its NeXT Personal from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings demonstrate that the company’s highly sensitive molecular residual disease (MRD) test, NeXT Personal, is a strong predictor of outcomes in patients with stage II-IIIb, EGFR-mutated non-small cell lung cancer (NSCLC) receiving neoadjuvant therapy.
TEM Stock Outperforms Industry & Benchmark
In the past year, Tempus AI shares have rallied 67.4%, outperforming the industry’s 21.4% growth and the S&P 500 composite’s 19.4% improvement.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 9.56X compared with the industry average of 5.88X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's loss per share estimate for 2025 has moved south 8 cents.
Image Source: Zacks Investment Research
TEM stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.